An oligonucleotide carrier based on β-1,3-glucans

Kazuo Sakurai; Seiji Shinkai

doi:10.1007/4-431-27879-6_9

An oligonucleotide carrier based on β-1,3-glucans

Kazuo Sakurai, Seiji Shinkai

Institute for Advanced Study

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

6 Conclusions: This study demonstrates the potential of SPG as an oligonucleotide carrier, for example, in antisense and CpG DNAs. The most distinguishing feature of this carrier compared to other cation types is that the driving force of the complexation is hydrogen bonds instead of electrostatic forces. Therefore, the total charge of the SPG/nucleotide complex is negative and there is no DNA-compaction problem in this system. Using chemically modified SPG, the antisense effect and CpG immunostimulatory response can be enhanced.

Original language	English
Title of host publication	Non-viral Gene Therapy
Subtitle of host publication	Gene Design and Delivery
Publisher	Springer-Verlag Tokyo
Pages	103-117
Number of pages	15
ISBN (Electronic)	9784431278795
ISBN (Print)	4431251227, 9784431251224
DOIs	https://doi.org/10.1007/4-431-27879-6_9
Publication status	Published - Jan 1 2005

All Science Journal Classification (ASJC) codes

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1007/4-431-27879-6_9

Cite this

@inbook{61068db21fc94179a9f0b5501fe1c99f,

title = "An oligonucleotide carrier based on β-1,3-glucans",

abstract = "6 Conclusions: This study demonstrates the potential of SPG as an oligonucleotide carrier, for example, in antisense and CpG DNAs. The most distinguishing feature of this carrier compared to other cation types is that the driving force of the complexation is hydrogen bonds instead of electrostatic forces. Therefore, the total charge of the SPG/nucleotide complex is negative and there is no DNA-compaction problem in this system. Using chemically modified SPG, the antisense effect and CpG immunostimulatory response can be enhanced.",

author = "Kazuo Sakurai and Seiji Shinkai",

year = "2005",

month = jan,

day = "1",

doi = "10.1007/4-431-27879-6_9",

language = "English",

isbn = "4431251227",

pages = "103--117",

booktitle = "Non-viral Gene Therapy",

publisher = "Springer-Verlag Tokyo",

}

TY - CHAP

T1 - An oligonucleotide carrier based on β-1,3-glucans

AU - Sakurai, Kazuo

AU - Shinkai, Seiji

PY - 2005/1/1

Y1 - 2005/1/1

N2 - 6 Conclusions: This study demonstrates the potential of SPG as an oligonucleotide carrier, for example, in antisense and CpG DNAs. The most distinguishing feature of this carrier compared to other cation types is that the driving force of the complexation is hydrogen bonds instead of electrostatic forces. Therefore, the total charge of the SPG/nucleotide complex is negative and there is no DNA-compaction problem in this system. Using chemically modified SPG, the antisense effect and CpG immunostimulatory response can be enhanced.

AB - 6 Conclusions: This study demonstrates the potential of SPG as an oligonucleotide carrier, for example, in antisense and CpG DNAs. The most distinguishing feature of this carrier compared to other cation types is that the driving force of the complexation is hydrogen bonds instead of electrostatic forces. Therefore, the total charge of the SPG/nucleotide complex is negative and there is no DNA-compaction problem in this system. Using chemically modified SPG, the antisense effect and CpG immunostimulatory response can be enhanced.

UR - http://www.scopus.com/inward/record.url?scp=84920077573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920077573&partnerID=8YFLogxK

U2 - 10.1007/4-431-27879-6_9

DO - 10.1007/4-431-27879-6_9

M3 - Chapter

AN - SCOPUS:84920077573

SN - 4431251227

SN - 9784431251224

SP - 103

EP - 117

BT - Non-viral Gene Therapy

PB - Springer-Verlag Tokyo

ER -

An oligonucleotide carrier based on β-1,3-glucans

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this